Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome-Coronavirus Spike Protein

Matthijs P. Raadsen, Christine Dahlke, Anahita Fathi, Mart M. Lamers, Petra van den Doel, Luca M. Zaeck, Martin E. van Royen, Erwin de Bruin, Reina Sikkema, Marion Koopmans, Eric C. M. van Gorp, Gerd Sutter, Rory D. de Vries, Marylyn M. Addo, Bart L. Haagmans*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)
57 Downloads (Pure)

Abstract

Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.

Original languageEnglish
Article numberjiad052
Pages (from-to)586-590
Number of pages5
JournalJournal of Infectious Diseases
Volume228
Issue number5
Early online date1 Mar 2023
DOIs
Publication statusPublished - 1 Sept 2023

Bibliographical note

Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Fingerprint

Dive into the research topics of 'Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome-Coronavirus Spike Protein'. Together they form a unique fingerprint.

Cite this